Month: April 2023

INSIDE INFORMATION Patent covers the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages BioSenic’s new formulation lowers the dosage of arsenic trioxide by combining it with copper salts to maintain therapeutic efficacy, with the potential of administration through multiple routes, including intravenous, oral and other novel routes of administration Mont-Saint-Guibert, Belgium, April 18, 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the issuance of a key new patent entitled ‘Use of metal ions to potentiate the therapeutic effects of arsenic’ (EP3972613) by the European Patent Office (EPO). BioSenic has recently announced the publication of new data...

In Q1 of 2023, AS LHV Group earned EUR 33.1 million in net profit, i.e., EUR 8.7 million more compared to last quarter (+36%) and EUR 20.7 million more compared to yoy (+167%). The return on equity attributable to the shareholders of LHV Group was 30.4% in Q1. Within the quarter, AS LHV Pank earned EUR 37.3 million in net profit. In Q1, AS LHV Varahaldus earned EUR 87 thousand euros in net profit. AS LHV Kindlustus generated a net loss of EUR 450 thousand and LHV UK Limited generated a net loss of EUR 2.5 million in the first quarter. Consolidated income of the Group in Q1 of 2023 was EUR 68.4 million, which is 21% more than in the previous quarter. Out of the income, EUR 55.1 million was net interest income and EUR 11.9 million net fee and commission income. The operating expenses of the consolidation group made EUR 30.6 million in Q1,...

Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, April 18, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, provided an updated timeline for its New Drug Application (NDA) submission for its antibiotic ceftobiprole to the US Food and Drug Administration (FDA). Basilea estimates that an additional three to six months of preparatory work will be required to ensure that one of its third-party contract manufacturing organizations (CMOs) is ready for inspection by the FDA, which is a prerequisite for an NDA review. Basilea, therefore, now expects to submit the NDA for the three indications of Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI),...

Taylor Transport Signs Binding Purchase Order To Purchase First Glīd Units Salt Lake City, UT, April 18, 2023 (GLOBE NEWSWIRE) — Genesis Electronics Group Announces First Binding Purchase Order Taylor Transport Signs Binding Purchase Order To Purchase First Glīd Units Salt Lake City, UT – April 17, 2023 – Genesis Electronics Group, Inc. (GEGI), the maker of the autonomous road-to-rail patent-pending shipping technology, Glīd, announced that it has signed Its first purchase order with Taylor Transport, of Vancouver, WA. The relationship between Taylor Transport and GEGI has progressed swiftly as the Companies have spent a significant amount of time together building out a solution for Taylor Transport to utilize Glīd’s autonomous vehicles to augment their existing transportation fleet. As previously announced, Taylor Transport’s...

Harvest volumes Q1 2023 (1)Farming Norway 65.5 thousand tonnesFarming Scotland 11.0 thousand tonnesFarming Chile 10.5 thousand tonnesFarming Canada 7.5 thousand tonnesFarming Ireland 1.0 thousand tonnesFarming Faroes 2.0 thousand tonnesFarming Iceland (Arctic Fish) 5.0 thousand tonnesTotal 102.5 thousand tonnes   In connection with the presentation of the Q4 2022 results, Mowi ASA guided a total harvest volume of 98 thousand tonnes (GWE) for Q1 2023. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWE). Additional information Operational EBIT for the Group was approximately EUR 322 million in Q1 2023 (EUR 207 million in Q1 2022). Total Operational EBIT per kg through the value chain was approximately as follows:Norway EUR 3.75Scotland EUR 2.45Chile EUR 1.50Canada EUR 2.15...

Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules SIKA PERFORMS WELL IN DEMANDING MARKETS: SLIGHT GROWTH IN LOCAL CURRENCIES IN FIRST QUARTERSales up by 1.2% in local currencies Q1 sales of CHF 2,325.9 million (-3.0% in CHF) Strong growth of 15.2% in Global Business (previous year: 10.4%) Negative currency effect of -4.2% Closing of MBCC acquisition still targeted for first half of 2023 Outlook for fiscal 2023 confirmedSales increase in local currencies by 6–8% Over-proportional increase in EBIT (excluding MBCC acquisition) Confirmation of 2023 strategic targets for sustainable, profitable growthDespite challenging economic conditions, Sika ended the first quarter of 2023 with a slight growth. Sales in local currencies and organic growth both increased by 1.2%. In Swiss franc terms, Sika...

DANVILLE, CA, April 17, 2023 (GLOBE NEWSWIRE) — Trio Petroleum Corp (“Trio”), an oil and gas exploration and development company focused on strategic, high growth energy projects in California, today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a price to the public of $3.00 per share. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are expected to be $6 million. In addition, the underwriters have been granted a 45-day option to purchase up to 300,000 additional shares of Common Stock to cover over-allotments. The common stock is expected to begin trading on The New York Stock Exchange American (“NYSE American”) under the symbol “TPET” on April 18, 2023, and the offering is expected to close on April 20, 2023, subject to the satisfaction...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. , April 17, 2023 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma in China has been accepted for review by the China National Medical Products Administration (“NMPA”). Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towards addressing the significant unmet medical need for gastric cancer patients. Gastric cancer is one of the most common cancers globally, with the highest incidence and mortality rates found in Asian populations. China alone accounts for...